Free Trial
NASDAQ:CLPT

ClearPoint Neuro Q3 2025 Earnings Report

ClearPoint Neuro logo
$26.27 +0.16 (+0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$26.19 -0.08 (-0.30%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro EPS Results

Actual EPS
N/A
Consensus EPS
-$0.20
Beat/Miss
N/A
One Year Ago EPS
N/A

ClearPoint Neuro Revenue Results

Actual Revenue
N/A
Expected Revenue
$9.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

ClearPoint Neuro Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

ClearPoint Neuro Earnings Headlines

Why “good news” from the Fed usually ends badly
The Fed just cut rates — and while it may look like good news on the surface, history shows what often comes next. Cheaper money fuels spending, inflation re-emerges, and markets face renewed turbulence. But volatility also creates opportunity. One veteran analyst says the coming rate cut cycle could open a window most traders will miss — and he’s sharing the #1 play designed to take advantage of it.tc pixel
ClearPoint Neuro: AMT-130 Highlights A Bright Future
ClearPoint Neuro: Selling The Tools For Brain Therapies
See More ClearPoint Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ClearPoint Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ClearPoint Neuro and other key companies, straight to your email.

About ClearPoint Neuro

ClearPoint Neuro (NASDAQ:CLPT) is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision. Its proprietary SmartFrame trajectory guide offers adjustable angulation under MRI control, allowing clinicians to navigate complex cranial anatomy without the need for multiple frame placements or CT scans. The company also provides disposables, such as biopsy and ablation cannulae, to complement its core guidance platform.

Founded in 2007 as a spin-out from Brigham and Women’s Hospital, ClearPoint Neuro has secured regulatory clearances in the United States and Europe and has installed its systems in leading academic medical centers worldwide. The company’s commercial operations and clinical training programs support neurosurgeons and imaging specialists in North America, Europe and select international markets, fostering broader adoption of MRI-guided stereotactic procedures.

ClearPoint Neuro is led by a management team with deep expertise in medical devices, imaging and neurosurgery. The company continues to invest in product enhancements and clinical research partnerships, aiming to expand the range of neurological conditions that can benefit from its real-time, image-guided therapy solutions.

View ClearPoint Neuro Profile

More Earnings Resources from MarketBeat